Recombinant Human B7-1 / CD80 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified), 100 µg

Background
B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Source
Recombinant Human B7-1, Mouse IgG2a Fc Tag (B71-H52A4) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # P33681-1).
Predicted N-terminus: Val 35

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 50.9 kDa. The protein migrates as 65-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation

Endotoxin
Less than 0.1 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein-Protein Interaction between CTLA-4 and B7-1"
Tsuihiji, Honda, Kojoh et al
Pharmaceuticals (Basel) (2022) 15 (12)
(2) "Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives"
Tuli, Garg, Choudhary et al
Mol Biol Rep (2022)6
(3) "Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis"
Pyo, Yoon, Ahn et al
Sci Rep (2022) 12 (1), 21319
Showing 1-3 of 6075 papers.